Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver Range Resources: A hidden gem in the mining industry (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Insmed Inc INSM

Healthcare Biotechnology
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs... see more

Recent & Breaking News (NDAQ:INSM)

Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update

PR Newswire February 22, 2024

Insmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference Call on Thursday, February 22, 2024

PR Newswire February 8, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire February 2, 2024

Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference

PR Newswire January 5, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire January 4, 2024

Insmed To Present at the 42nd Annual J.P. Morgan Healthcare Conference

PR Newswire January 2, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire December 5, 2023

Insmed To Present at the Nasdaq 49th Investor Conference

PR Newswire November 29, 2023

Insmed To Present at Two November Conferences

PR Newswire November 8, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire November 3, 2023

Insmed Holds Second Annual Global Day of Good to Benefit Communities Across the Globe

PR Newswire November 2, 2023

Insmed Ranks No. 1 on Science's 2023 Top Biopharma Employers List

PR Newswire October 26, 2023

Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update

PR Newswire October 26, 2023

Insmed and Google Cloud Collaborate to Transform the Lives of Patients by Harnessing the Power of AI

PR Newswire October 24, 2023

Insmed to Host Third-Quarter 2023 Financial Results Conference Call on Thursday, October 26, 2023

PR Newswire October 12, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire October 6, 2023

Insmed To Present at Chardan's 7th Annual Genetic Medicines Conference

PR Newswire September 26, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire September 8, 2023

Insmed To Present at the Morgan Stanley 21st Annual Global Healthcare Conference

PR Newswire September 6, 2023

INSMED ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ARISE STUDY OF ARIKAYCE® (AMIKACIN LIPOSOME INHALATION SUSPENSION) IN PATIENTS WITH NTM LUNG DISEASE CAUSED BY MAC

PR Newswire September 5, 2023